Evaluation of Ornithine Decarboxylase and Ferric Reducing Capacity Levels as Potential Biomarkers for Polycystic Ovary Syndrome

Background: Polycystic ovary syndrome (PCOS) is a prevalent hormonal disorder affecting reproductive-age women, often linked to metabolic issues like insulin resistance. Objective: this study aimed to evaluate ornithine decarboxylase (ODC) and ferric reducing capacity (FRC) levels in women with PCOS, with assess the effects of metformin and Primolut N treatment on their levels. Subjects and Methods: A case−control study was conducted with 150 married Iraqi women, categorized into three groups: 50 healthy controls, 50 untreated PCOS, 50 treated PCOS. Blood samples were analyzed for ODC, FRC levels and hormonal profiles. Statistical analysis applied independent t-test, Pearson’s correlation, ROC curve. Results: The ODC level was significantly increased while the FRC level was substantially decreased in PCOS patients compared to controls. Under metformin and Primolut N treatment, both ODC and FRC concentrations were improved to be close to their levels in control group. This reveals the potential role of ODC and FRC in PCOS progression. ROC results showed perfect sensitivity and specificity of ODC and FRC in PCOS diagnosing. Conclusions: The study introduces ODC and FRC as a valuable biomarker for diagnosing PCOS, highlighting its role in the disorder’s pathophysiology.